Patients with
ST-segment elevation myocardial infarction (
STEMI) and concurrent
coronavirus disease 2019 (COVID-19) have been reported to have poor outcomes. However, previous studies are small and limited. The National Inpatient Sample database for the year 2020 was queried to identify all adult hospitalizations with a primary diagnosis of
STEMI, with and without concurrent
COVID-19. A 1:1 propensity score matching was performed. A total of 159,890 hospitalizations with a primary diagnosis of
STEMI were identified. Of these, 2210 (1.38%) had concurrent
COVID-19. After propensity matching,
STEMI patients with concurrent
COVID-19 had a significantly higher mortality (17.8% vs 9.1%, OR 1.96, P< 0.001), lower likelihood to receive same-day
percutaneous coronary intervention (PCI) (63.6% vs 70.6%, P = 0.019), with a trend towards lower overall PCI (74.9% vs 80.2%, P = 0.057) and significantly lower
coronary artery bypass grafting) (3.0% vs 6.8%, P = 0.008) prior to discharge, compared with
STEMI patients without
COVID-19. The prevalence of
cardiogenic shock, need for mechanical circulatory support,
extracorporeal membrane oxygenation,
cardiac arrest,
acute kidney injury (AKI), dialysis, major
bleeding and
stroke were not significantly different between the groups.
COVID-19-positive
STEMI patients who received same-day PCI had significantly lower odds of in-hospital mortality (adjusted OR 0.42, 95% CI 0.20-0.85, P = 0.017).
STEMI patients with concurrent
COVID-19 infection had a significantly higher (almost 2 times) in-hospital mortality, and lower likelihood of receiving same-day PCI, overall (any-day) PCI, and CABG during their admission, compared with
STEMI patients without
COVID-19.